HC Bioscience

Background:

HC Bioscience came to Ten Bridge when it was preparing to announce lead indications and take initial regulatory steps to reach the clinic. Launched in 2021, the company’s protein editing technology enables cells to produce functional proteins from faulty genes. Since its founding, HC Bioscience has translated academic research into a drug development platform with a lead program in hemophilia A as well as programs in Duchenne muscular dystrophy and oncology, and is positioned to be the first to test protein editing in human trials. To reflect this progress, HC Bioscience sought a rebrand that emphasized the company’s clinical focus with a fresh logo and website, as well as a communications strategy centered on its scientific progress and commitment to patients.

Strategy:

HC Bioscience and TBC worked closely to craft a brand and messaging that would appeal to patient communities, investors, potential partners and others. At the heart of story was the company’s elegant approach to genetic medicine based on tRNAs—naturally occurring molecular interpreters that translate genetic information into proteins. Instead of correcting defects in DNA or mRNA, engineered tRNAs enable the cell to overwrite disease-causing mutations. Through this protein editing approach, HC Bioscience aims to bypass limitations and safety concerns associated with some gene editing technologies and open the door to genetic medicine for patients who would otherwise be left behind.

When developing HC Bioscience’s new website, TBC created engaging scientific illustrations to make this previously underappreciated area of biology come to life and highlight key advantages protein editing holds over other treatment options. A distinct programs page with accessible information on HC’s approach and progress towards the clinic lays out a compelling path to patient impact.

Outcomes:

HC Bioscience’s new brand and website launched in June 2024, shortly after the first public announcements of the company’s programs in severe Hemophilia A and Duchenne muscular dystrophy. The rebrand, introducing a more advanced and evolved company, provided the team with another important tool for investor conversations, recruiting, and communicating with external stakeholders by highlighting HC Bioscience’s science, team, and drive to pioneer a new category of medicine.